Selonsertib治疗糖尿病肾病:2b期随机活性导入临床试验
MOSAIC研究纳入310例2型糖尿病合并CKD患者,随机接受selonsertib 18mg或安慰剂每日一次,评估eGFRcr斜率变化。结果显示selonsertib组eGFRcr下降减慢但肾脏临床事件和AKI报告率数值更高,需更大样本更长随访评估获益风险。
要点
- selonsertib组第84周eGFRcr斜率差异为1.20 ml/min/1.73m²/年,P=0.14未达预设显著性。
- selonsertib组肾脏临床事件17% vs 安慰剂12%,差异4.7%(95%CI -6.3%至15.9%)。
- 研究者报告的AKI最常见,selonsertib组11.0/100患者年 vs 安慰剂5.9/100患者年。
核心结论
- selonsertib减缓eGFRcr下降,但肾脏临床事件和研究者报告的AKI数值更高。
研究设计与样本
- 2b期随机安慰剂对照试验,纳入310例2型糖尿病合并CKD成人患者(selonsertib组154例,安慰剂组156例)。
- 入选标准为eGFR 20至<60 ml/min/1.73m²且UACR 150–5000 mg/g,已用最大耐受剂量ACEI或ARB。
- 4周selonsertib导入期建立治疗特异性基线eGFRcr,随机1:1接受selonsertib 18mg或安慰剂每日一次。
- 随访至最后随机患者完成48周,主要疗效终点为治疗特异性基线至第84周eGFRcr斜率差异,预设双侧P=0.30。
主要发现
- 第84周selonsertib与安慰剂eGFRcr斜率平均差异为1.20 ml/min/1.73m²/年(95%CI -0.41至2.81;P=0.14)。
- 肾脏临床事件(eGFRcr较导入前基线下降≥40%、肾衰竭或肾脏病死亡)selonsertib组17%(26/154)vs 安慰剂组12%(19/156),差异4.7%(95%CI -6.3%至15.9%)。
- 研究者报告的最常见不良事件为AKI,selonsertib组11.0/100患者年,安慰剂组5.9/100患者年。
临床怎么用
- selonsertib在2型糖尿病合并中晚期CKD患者中虽减缓eGFRcr下降,但肾脏临床事件和AKI报告率数值更高,需权衡获益与风险。
局限性
- 主要终点采用预设双侧P=0.30的宽松显著性阈值。
- 肾脏临床事件和AKI差异为数值性,置信区间宽,需更大样本更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In a randomized, placebo-controlled, phase 2b study, we compared the effects of selonsertib with placebo on eGFR decline in people with type 2 diabetes and CKD. Patients taking selonsertib had slower eGFR decline but were more likely to reach a composite kidney outcome and report AKI. A larger trial with longer-term follow-up would more precisely assess the relative benefits and risks of selonsertib in this setting. BACKGROUND: Selonsertib is an apoptosis signal–regulating kinase 1 inhibitor that reduces inflammation, fibrosis, and apoptosis. The MOSAIC study evaluated whether selonsertib attenuated kidney function decline in patients with diabetic kidney disease. METHODS: We conducted a phase 2b study in adults with type 2 diabetes and eGFR 20 to <60 ml/min per 1.73 m2 with urine albumin-creatinine ratio 150–5000 mg/g on maximum tolerated dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. To account for an acute selonsertib-related decrease in serum creatinine–based eGFR (eGFRcr), patients entered a 4-week selonsertib run-in period to establish treatment-specific baseline eGFRcr. Patients were randomized 1:1 to selonsertib 18 mg or matching placebo once daily. We followed all participants up until the last randomized participant completed 48 weeks of follow-up. The primary efficacy outcome was the difference in eGFRcr slopes from treatment-specific baselines to week 84, evaluated at a prespecified two-sided P = 0.30. We also evaluated kidney clinical events (eGFRcr ≥40% decline from pre–run-in baseline, kidney failure, or death due to kidney disease) and adverse events. RESULTS: In total, 310 patients were randomized (selonsertib n=154, placebo n=156; 68% male, mean age 65 years, mean baseline eGFRcr 35 ml/min per 1.73 m2). Mean difference between selonsertib and placebo eGFRcr slopes at week 84 was 1.20 ml/min per 1.73 m2 per year (95% confidence interval, −0.41 to 2.81; P = 0.14). Kidney clinical events occurred in 17% (26/154) of patients randomized to selonsertib and 12% (19/156) of those randomized to placebo (difference 4.7%; 95% confidence interval, −6.3% to 15.9%). The most common investigator-reported adverse event was AKI (selonsertib 11.0/100 and placebo 5.9/100 patient-years). CONCLUSIONS: Selonsertib attenuated the decline in eGFRcr over up to 84 weeks; however, it resulted in a numerically higher number of patients reaching a kidney clinical event and a numerically higher rate of investigator-reported AKI. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease (MOSAIC), NCT04026165.
引用
- Heerspink HJL, Perkovic V, Tuttle KR, et al. Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial. J Am Soc Nephrol. 2024. PMID: 39018154. doi:10.1681/ASN.0000000000000444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。